|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
SYMPATHOMIMETICS TEND TO PRODUCE HYPERGLYCEMIA LEADING TO LOSS OF DIABETES CONTROL
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
BETABLOCKERS CONCOMITANT USE MAY CAUSE SEVERE HYPERTENSION SINCE BETABLOCKERS OPPOSE THE BETA ADRENERGIC ACTION OF SYMPATHOMIMETICS
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
HYPOKALEMIC EFFECT OF CORTICOSTEROIDS IS POTENTIATED
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION MAY INCREASE CHANCES OF HYPOKALEMIA
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CO-ADMINISTRATION OF DIGOXIN AND SYMPATHOMIMETICS INCREASES THE RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
CONCOMITANT USE MAY HAVE INCREASED RISK OF CARDIAC ARRHYTHMIAS
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|
SYMPATHOMIMETICS HYPERTENSIVE EFFECT IS POTENTIATED BY THE TRICYCLIC ANTIDEPRESSANTS LEADING TO PROLONGED SEVERE HYPERTENSION
|